Genmab — August 2018
-
God morgen
-
hey @StockBull , can you lift your limit a bit this week? I am getting a bit tired of it stopping at 1075... "22/8 13:30
by StockBull
1075 "
-
@EL. TA looks good and with MAIA hopefully around the corner I see at at least 1300 provided the data is good. With the recent share price fall, potential success of the MAIA and CASSIOPIEA trials in frontline MM is no longer reflected. Therefore, positive read outs in coming weeks could be key catalysts as they could help to calm any competition concerns embedded in the present share price.
-
Also looking forward to update on RA at CMD that Genmab are hosting on 26th September at their new R&D headquarters in Utrecht, Netherland as well as how Genmab see the Darzalex market developing as well as a focus on the early stage proprietary programme including updates on Tisotumab Vedotin, AXL-ADC, CD3xCD20 and DR5:DR5 Hexabod
-
Lidt mere. MM estimat 2018 30.770 i USA. Amy 4500. http://amyloidosis.org/facts/al/
-
-
Tænker i resultater fra Mai studiet kan lande når som helst? Krydser selvfølgelig fingre og satser på gode data.
-
Puha bliver spændende, mildest talt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind